Q1 EPS Estimates for AstraZeneca Increased by Zacks Research

AstraZeneca PLC (NASDAQ:AZN) – Analysts at Zacks Research boosted their Q1 2025 earnings estimates for AstraZeneca in a research note issued on Monday, December 30th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $1.07 per share for the quarter, up from their previous forecast of $1.06. The consensus estimate for AstraZeneca’s current full-year earnings is $4.11 per share.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter last year, the company posted $0.87 EPS. The business’s quarterly revenue was up 18.0% on a year-over-year basis.

A number of other equities analysts have also recently weighed in on AZN. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Trading Down 0.1 %

NASDAQ AZN opened at $65.52 on Wednesday. The stock’s 50-day simple moving average is $67.38 and its two-hundred day simple moving average is $75.57. AstraZeneca has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $203.15 billion, a price-to-earnings ratio of 31.35, a PEG ratio of 1.19 and a beta of 0.45.

Hedge Funds Weigh In On AstraZeneca

A number of hedge funds have recently modified their holdings of the company. McClarren Financial Advisors Inc. increased its stake in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after buying an additional 247 shares during the period. GHP Investment Advisors Inc. purchased a new position in AstraZeneca during the 2nd quarter valued at $26,000. Capital Performance Advisors LLP bought a new position in AstraZeneca in the 3rd quarter worth $28,000. Groupama Asset Managment lifted its position in shares of AstraZeneca by 22.9% in the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after purchasing an additional 101,225 shares during the period. Finally, Ashton Thomas Securities LLC bought a new stake in shares of AstraZeneca during the 3rd quarter valued at about $45,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.